Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon
PurposeThe burden of breast cancer is still growing in the Middle East and North Africa (MENA). BC patients typically present with more advanced stages than in Western countries. Limited information is available regarding the safety and efficacy of novel molecules for advanced BC in the Middle East...
Saved in:
| Main Authors: | Anwar Al Nouri, Faisal Al Terkait, Nagi El Saghir, Hady Ghanem, Joseph Kattan, Cynthia Bishouti, Jade Dreyer, Soniya Rai, Alexandru Rosca |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1437380/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
by: Sara M. Tolaney, et al.
Published: (2025-03-01) -
Risk factors for adverse reactions caused by abemaciclib in breast cancer therapy
by: Xianghua Quan, et al.
Published: (2025-06-01) -
Abemaciclib and Letrozole in Metastatic Male Breast Cancer
by: Leon Schönfeld, et al.
Published: (2024-11-01) -
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01) -
Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer
by: Maria Rosaria Valerio, et al.
Published: (2025-02-01)